Skip to content

A real-world clinical study of different surgical treatment for rectovaginal endometriosis

A real-world clinical study of different surgical treatment for rectovaginal endometriosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300074451
Enrollment
Unknown
Registered
2023-08-07
Start date
2023-06-20
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Interventions

Transvaginal surgery group:no
Transabdominal or laparoscopic surgery group :no

Sponsors

Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Informed consent has been signed (2) Women of reproductive age: 20-45 years old (3) Obvious clinical symptoms: such as dysmenorrhea, pain during intercourse, pain in bowel movements, and anal distention, etc., tuberous mass in rectovaginal septum (=1cm) or visible blue-purple nodules can be found in the posterior fornix of vagina. (4) Imaging examination (ultrasound or MRI) revealed nodular mass in the rectovaginal septum, which is consistent with the symptoms of endometriosis (5) The pathological diagnosis after surgery is rectovaginal endometriosis (6) Clear indications for surgery

Exclusion criteria

Exclusion criteria: (1) Patients who participate in other interventional research projects outside of routine clinical treatment (2) Patients with poor living condition, incapacitation or loss of consciousness. (3) Patients who refused to participate in the study. (4) Patients with concomitant or diagnosed malignant tumor. (5) Patients with obstructive intestinal abnormalities were identified (6) Patients with other intestinal diseases or previous history of intestinal surgery (7) Co-existing diseases or taking related drugs that may affect intestinal function (8) There is contraindication of hormone drugs

Design outcomes

Primary

MeasureTime frame
Health-related quality of life;

Secondary

MeasureTime frame
the relief of pain associated with endometriosis;The number and proportion of patients with symptoms such as constipation, anal dropsy and distension, and posterior tenesmus;the time of recurrence and the proportion of reoperation;change of the rectovaginal endometriosis lesion;Gastrointestinal quality of life index;the number and percentage of adverse events and serious adverse events after surgery;he change of CA125,CA199,AMH, six sex hormones before and after operation;Proportion of patients who require medication before and after surgery;The direct economic costs of different treatments;The patient's overall impression of the treatment effect;

Countries

China

Contacts

Public ContactYi Dai

Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences

jacquedai@vip.sina.com+86 186 1102 7788

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026